GlassScriptPhysician profile
Clark C Kulig
NPI 1669423430
$2,852.46
in general payments reported to CMS, 2019-2025
23 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.88 · 2022: $551 · 2023: $240 · 2024: $806 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $490.52 | 2023-2025 | Iqirvo, Bylvay |
| Boston Scientific Corporation | $469.46 | 2022-2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Mallinckrodt Hospital Products INC. | $322.91 | 2022-2025 | Terlivaz |
| Gilead Sciences, INC. | $206.79 | 2023-2025 | Livdelzi |
| Abbvie INC. | $204.20 | 2022-2025 | |
| Medtronic, INC. | $173.21 | 2025 | Osteocool Rf Ablation System, Signia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.77 | 2022-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $160.49 | 2019-2025 | |
| Orphalan INC | $150.26 | 2025 | Cuvrior |
| Echosens North America, INC. | $134.37 | 2022-2024 | Fibroscan |
| Madrigal Pharmaceuticals | $63.66 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $42.00 | 2024-2025 | Livtencity |
| Novo Nordisk INC | $34.59 | 2025 | Ozempic |
| Lilly USA, LLC | $33.29 | 2025 | Mounjaro |
| Dilon Technologies, INC. | $29.44 | 2024 | Hemoblast Bellows |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $28.31 | 2023 | Avastin, Tecentriq |
| Alexion Pharmaceuticals, INC. | $27.34 | 2025 | Ultomiris |
| Kamada LTD. | $25.49 | 2025 | |
| Merck Sharp & Dohme LLC | $22.28 | 2024 | Prevymis |
| Avanos Medical | $20.98 | 2022 | |
| Mirum Pharmaceuticals, INC. | $18.91 | 2023 | Livmarli |
| Invivyd INC | $17.78 | 2025 | Pemgarda |
| Astrazeneca Pharmaceuticals LP | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clark Kulig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.